Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

DGAP-News: EVOTEC TO ATTEND UPCOMING INVESTOR CONFERENCES

DGAP-News: EVOTEC TO ATTEND UPCOMING INVESTOR CONFERENCES

DGAP-News: Evotec SE / Key word(s): Conference
EVOTEC TO ATTEND UPCOMING INVESTOR CONFERENCES
14.11.2019 / 11:27
The issuer is solely responsible for the content of this announcement.


 

Hamburg, Germany, 14 November 2019:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that its management will be presenting at and attending the following upcoming conferences in November and December 2019:

Jefferies London Healthcare Conference, London, UK

  • Date: Wednesday, 20 November 2019
  • Presentation: 20 November 2019, 8.00 am (GMT)
  • Venue: London, UK
  • Attendee: Enno Spillner, Chief Financial Officer
     

LBBW German Company Day, London, UK

  • Date: Thursday, 21 November 2019
  • Venue: London, UK
  • Attendee: Enno Spillner, Chief Financial Officer
     

German Equity Forum, Frankfurt, Germany

  • Date: Monday, 25 November 2019
  • Presentation: 25 November 2019, 11.30 am (CET)
  • Venue: Frankfurt am Main, Germany
  • Attendee: Dr Werner Lanthaler, Chief Executive Officer


Kempen's London Conference, London, UK

  • Date: Wednesday, 27 November 2019
  • Venue: London, UK
  • Attendee: Dr Werner Lanthaler, Chief Executive Officer
     

Berenberg European Corporate Conference, Surrey, UK

  • Date: Tuesday, 03 December 2019
  • Presentation: 03 December 2019, 11.00 am (GMT)
  • Venue: Surrey, UK
  • Attendee: Enno Spillner, Chief Financial Officer

 

ABOUT EVOTEC SE
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 2,900 employees provide the highest quality
stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. On this basis, Evotec has built a broad and deep pipeline of approx. 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Celgene, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to www.evotec.com and follow us on Twitter @Evotec.
 

FORWARD LOOKING STATEMENTS
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

Contact Evotec SE:
Gabriele Hansen, SVP Corporate Communications, Marketing & Investor Relations, Phone: +49.(0)40.56081-255, gabriele.hansen@evotec.com

 



14.11.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Evotec SE
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: MDAX, TecDAX
Listed: Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 912893

 
End of News DGAP News Service

912893  14.11.2019 

fncls.ssp?fn=show_t_gif&application_id=912893&application_name=news&site_id=sharewise

Evotec AG Stock

€23.80
-1.290%
We can see a decrease in the price for Evotec AG. Compared to yesterday it has lost -€0.200 (-1.290%).
With 35 Buy predictions and 1 Sell predictions Evotec AG is one of the favorites of our community.
With a target price of €27.00 there is a slightly positive potential of 13.445% for Evotec AG compared to the current price of €23.80.
Like: 0
Share

EQS Group is a leading international provider of regulatory technology in the fields of corporate compliance and investor relations. In working with EQS Group, thousands of companies worldwide inspire trust by fulfilling complex national and international disclosure obligations, minimizing risks and communicating transparently with stakeholders.




Comments

You may not comment on this article as you either did not confirm your account yet or were blocked. If you think this is a mistake please contact us. Show more